The National Myelodysplastic Syndromes (MDS) Study.

• Suspected (e.g., persistent unexplained cytopenia, circulating peripheral
blasts etc.) MDS or MDS/MPN overlap disorders and undergoing diagnostic
work-up with planned bone marrow assessments OR
• Diagnosed with de novo or therapy-related MDS within 6-months of
enrollment per the World Health Organization (WHO) criteria1 and undergoing
clinical evaluation and planned bone marrow assessments to confirm MDS or
to evaluate disease status
• Bone marrow aspirate expected to be performed within 1 week of registration,
and in all cases must be performed no later than 4 weeks after enrollment
• Age 18 or older
• No prior treatment for MDS at entry and through the time of the entry bone
marrow aspirate
• No treatment with hematopoietic growth factors in prior 6 months
• B12 level, serum folate, ferritin, and Thyroid-Stimulating Hormone (TSH) tests
performed in prior 6 months
• No diagnosis of a solid tumor or hematologic malignancy within two years
prior to enrollment except for in situ cancer of the skin (basal or squamous
cell), cervix, bladder, breast, or prostate
• No treatment with radiation therapy in the two years prior to registration
• No non-hormonal treatment for malignancy within the two years prior to
• No established hereditary bone marrow failure syndrome
• No known primary diagnosis of aplastic anemia, classical paroxysmal
nocturnal hemoglobinuria, amegakaryocytic thrombocytopenic purpura, or
large granular lymphocyte leukemia
• Not enrolled in the Connect® MDS/AML Disease Registry
Cancer, All Other
Alison Conlin, M.D.
Laurie Delanty

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.